NASDAQ: PTGX · Biotechnology
Protagonist Therapeutics (PTGX) fair value: undervalued or overvalued?
As of 16 Nov 2026, Faircurve's model values Protagonist Therapeutics (PTGX) at $104.97 a share. The stock last closed at $124.67, which puts the model's fair value 15.8% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 17 Nov 2026. Protagonist Therapeutics, Inc.
The report adds the live price, the chart against the range the options market prices and the next earnings date. No account needed.
This week, in three parts
What happenedThe run of 16 Nov 2026 moved the fair value from $106.93 to $104.97 (-1.8%). The move is not broken down.
What the model makes of itThe price of $124.67 is 15.8% above it: Overvalued, on a medium evidence grade.
What's nextNext report on 24 Feb 2027. Options prices imply a move of about 12% either way over the next month. On the model's Scorecard Leaders list since 2 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give PTGX?
The calibrated range for PTGX over 63 trading days is $108.66 to $144.03. It sits around the last close, and its width comes from the volatility that PTGX's own options imply (42% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $69.20 to $156.88. In 33% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 16 Nov 2026
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. It sits in the healthcare sector, under biotechnology.
Faircurve's model put the fair value at $104.97 a share on 16 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $106.93, so the fair value moved -1.8%. The model's reason: the move is not broken down. The calibrated range over 63 trading days is $114.66 to $150.56. It is built around the price from the volatility the stock's own options imply, calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations refreshed on 14 Nov 2026. The evidence grade is Medium. The grade reflects input completeness, peer count and agreement, and range width. It does not test whether the fair value is right.
Protagonist scores 55 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Profitability scores 100, with ROIC of 53.0% against a peer median of -36.3%. Stability scores 0, with 5y EBITDA margin downside volatility of 131.5 pts against a peer median of 32.7 pts. The model compares it with TG Therapeutics, Inc. (TGTX), BioMarin Pharmaceutical Inc. (BMRN) and Bio-Techne Corporation (TECH).
Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does PTGX report earnings, and how has the stock reacted?
Protagonist Therapeutics's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
Options prices on 17 Nov 2026 imply a move of about 9.5% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. PTGX's 30 day implied volatility works out to about 12.0% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PTGX's last 8 reports, ignoring direction, was 5.0%.
What the options market has priced for a month's move in PTGX
How does PTGX score on business quality?
Protagonist Therapeutics's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 53.0%ROIC | -36.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 17 | 0.32xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 23 | -89.4%Revenue growth, trailing | 66.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 75 | 0.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -1.39xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 131.5 ptsEBITDA margin downside volatility, 5y | 32.7 pts |
How does PTGX compare with similar companies?
The companies in biotechnology closest to Protagonist Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | $298.55 | $352.42 | +18.0% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $51.65 | $63.03 | +22.0% | Low evidence grade |
| TGTX TG Therapeutics, Inc. | $62.71 | $75.36 | +20.2% | Undervalued |
| ARWR Arrowhead Pharmaceuticals, Inc. | $42.99 | $53.67 | +24.8% | Low evidence grade |
| BMRN BioMarin Pharmaceutical Inc. | $58.51 | $69.09 | +18.1% | Undervalued |
| HALO Halozyme Therapeutics, Inc. | $95.97 | $111.93 | +16.6% | Low evidence grade |
| TECH Bio-Techne Corporation | $72.63 | $65.76 | -9.5% | Fairly valued |
| LGND Ligand Pharmaceuticals Incorporated | $293.81 | $282.99 | -3.7% | Low evidence grade |
What the comparable companies' multiples alone would give for PTGX, the peer-implied price, is $208.38 a share on this run. The fair value weighs that against the company's own multiple.
Protagonist Therapeutics at a glance
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.
- Market value
- $8.5B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta to the US market
- 0.87
- First valued by Faircurve
- 11 Jul 2026
At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. PTGX was not among them.
How the fair value is worked out: the model prices Protagonist Therapeutics on the price of comparable companies relative to their profits (a peer multiple), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for PTGX was $106.93. As of 16 Nov 2026 it is $104.97, a change of -1.8%. The move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Protagonist Therapeutics's valuation
Is Protagonist Therapeutics stock undervalued or overvalued?
On Faircurve's model, PTGX reads as Overvalued as of 16 Nov 2026. The model's fair value is $104.97 a share against a last close of $124.67, a gap of -15.8%.
What is PTGX's fair value?
$104.97 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $69.20 to $156.88.
What price range does the model give PTGX?
$108.66 to $144.03 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Protagonist Therapeutics report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has PTGX moved on past earnings reports?
Across its last 8 reports the median two session move was 5.0%, ignoring direction. The largest was -7.9% around the report of 5 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for PTGX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on PTGX
The model has an idea open on PTGX under Scorecard Leaders since 2 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PTGX with their outcomes. A free account is enough.